Vaccines for COVID-19

Author:

Tregoning J S1ORCID,Brown E S1,Cheeseman H M1ORCID,Flight K E1ORCID,Higham S L1ORCID,Lemm N-M1,Pierce B F1ORCID,Stirling D C1ORCID,Wang Z1ORCID,Pollock K M1ORCID

Affiliation:

1. Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK

Abstract

Summary Since the emergence of COVID-19, caused by the SARS-CoV-2 virus at the end of 2019, there has been an explosion of vaccine development. By 24 September 2020, a staggering number of vaccines (more than 200) had started preclinical development, of which 43 had entered clinical trials, including some approaches that have not previously been licensed for human vaccines. Vaccines have been widely considered as part of the exit strategy to enable the return to previous patterns of working, schooling and socializing. Importantly, to effectively control the COVID-19 pandemic, production needs to be scaled-up from a small number of preclinical doses to enough filled vials to immunize the world's population, which requires close engagement with manufacturers and regulators. It will require a global effort to control the virus, necessitating equitable access for all countries to effective vaccines. This review explores the immune responses required to protect against SARS-CoV-2 and the potential for vaccine-induced immunopathology. We describe the profile of the different platforms and the advantages and disadvantages of each approach. The review also addresses the critical steps between promising preclinical leads and manufacturing at scale. The issues faced during this pandemic and the platforms being developed to address it will be invaluable for future outbreak control. Nine months after the outbreak began we are at a point where preclinical and early clinical data are being generated for the vaccines; an overview of this important area will help our understanding of the next phases.

Funder

Engineering and Physical Sciences Research Council

Publisher

Oxford University Press (OUP)

Subject

Immunology,Immunology and Allergy

Reference225 articles.

1. A novel coronavirus from patients with pneumonia in China, 2019;Zhu;N Engl J Med,2020

2. Coronavirus envelope protein: current knowledge;Schoeman;Virol J,2019

3. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation;Wrapp;Science,2020

4. The SARS-CoV-2 spike protein has a broad tropism for mammalian ACE2 proteins;Conceicao;bioRxiv,2020

5. Presumed Asymptomatic Carrier Transmission of COVID-19;Bai;JAMA,2020

Cited by 191 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3